Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
申请人:Santhera Pharmaceuticals (Schweiz) AG
公开号:EP2210885A1
公开(公告)日:2010-07-28
The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression, nausea and emesis.
本发明涉及取代杂环芳基哌啶衍生物作为黑色素皮质素-4受体调节剂,特别是作为黑色素皮质素-4受体拮抗剂。这些拮抗剂可用于治疗由癌症、慢性肾病(CKD)或慢性心力衰竭(CHF)引起的消瘦症、肌肉消耗、由化疗或放疗引起的厌食症、神经性厌食症、肌萎缩侧索硬化症(ALS)、疼痛、神经性疼痛、焦虑和抑郁症、恶心和呕吐等疾病和疾病的治疗。